The average one-year price target for Belite Bio, Inc – Depositary Receipt (NasdaqCM:BLTE) has risen to $215.73 per share, an 11.24% increase from the previous estimate of $193.93, dated February 21, 2026. This new target reflects a significant rise of 41.53% from the latest closing price of $152.43 per share, with analyst targets ranging from a low of $186.85 to a high of $279.30.
Institutional ownership in Belite Bio has surged, with 70 funds reporting positions—an increase of 59.09% in the last quarter. Total shares owned by institutions jumped 212.30% to 7,196K shares, with an average portfolio weight dedicated to BLTE increasing 348.75% to 0.45%.
Key institutional changes include Darwin Global Management holding 3,028K shares and Rtw Investments increasing its holdings from 312K to 715K shares, a rise of 56.31%. Millennium Management significantly increased its holdings from 21K to 559K shares, while Ra Capital Management reduced its stake from 875K to 432K shares.
